203 related articles for article (PubMed ID: 28627767)
1. Clinical significance of post-progression survival in lung cancer.
Imai H; Kaira K; Minato K
Thorac Cancer; 2017 Sep; 8(5):379-386. PubMed ID: 28627767
[TBL] [Abstract][Full Text] [Related]
2. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
[TBL] [Abstract][Full Text] [Related]
4. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
[TBL] [Abstract][Full Text] [Related]
5. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.
Imai H; Takahashi T; Mori K; Ono A; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N
Neoplasma; 2014; 61(2):233-40. PubMed ID: 24299320
[TBL] [Abstract][Full Text] [Related]
6. The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer.
Miura Y; Imai H; Sakurai R; Kaira K; Sunaga N; Minato K; Saito R; Hisada T
Med Oncol; 2018 Mar; 35(4):45. PubMed ID: 29508094
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.
Imai H; Mori K; Watase N; Fujimoto S; Kaira K; Yamada M; Minato K
Can Respir J; 2016; 2016():5405810. PubMed ID: 27445549
[TBL] [Abstract][Full Text] [Related]
8. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Kawase I
Asia Pac J Clin Oncol; 2015 Jun; 11(2):121-8. PubMed ID: 24811212
[TBL] [Abstract][Full Text] [Related]
9. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer.
Hayashi H; Okamoto I; Morita S; Taguri M; Nakagawa K
Ann Oncol; 2012 Jun; 23(6):1537-41. PubMed ID: 22039091
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.
Imai H; Yamaguchi O; Mori K; Hashimoto K; Akagami T; Shinomiya S; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
Thorac Cancer; 2021 Apr; 12(8):1171-1179. PubMed ID: 33626218
[TBL] [Abstract][Full Text] [Related]
11. Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin.
Imai H; Kaira K; Mori K; Watase N; Hisada T; Yamada M; Minato K
J Cancer Res Ther; 2020; 16(4):764-770. PubMed ID: 32930116
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer.
Yoshino R; Imai H; Mori K; Tomizawa Y; Takei K; Tomizawa M; Kaira K; Yoshii A; Watanabe S; Saito R; Yamada M
J Cancer Res Ther; 2015; 11(3):606-11. PubMed ID: 26458589
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy.
Imai H; Kobayashi D; Kaira K; Kawashima S; Masubuchi K; Murata M; Ebara T; Kitamoto Y; Minato K
Radiol Oncol; 2022 Feb; 56(2):228-237. PubMed ID: 35218691
[TBL] [Abstract][Full Text] [Related]
15. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
[TBL] [Abstract][Full Text] [Related]
16. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.
Kasuga A; Hamamoto Y; Takeuchi A; Kawasaki K; Suzuki T; Hirata K; Sukawa Y; Takaishi H; Kanai T
Cancer Chemother Pharmacol; 2017 Mar; 79(3):595-602. PubMed ID: 28236000
[TBL] [Abstract][Full Text] [Related]
17. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
18. Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K; Imai H; Wasamoto S; Tsuda T; Minemura H; Nagai Y; Yamada Y; Kishikawa T; Umeda Y; Shiono A; Takechi H; Shiihara J; Kaira K; Kanazawa K; Taniguchi H; Kaburagi T; Kagamu H; Minato K
Thorac Cancer; 2022 Oct; 13(19):2776-2785. PubMed ID: 36062426
[TBL] [Abstract][Full Text] [Related]
19. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
[TBL] [Abstract][Full Text] [Related]
20. Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.
Shimokawa M; Kogawa T; Shimada T; Saito T; Kumagai H; Ohki M; Kaku T
J Cancer; 2018; 9(5):872-879. PubMed ID: 29581765
[No Abstract] [Full Text] [Related]
[Next] [New Search]